Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALMA Study
2024-513084-38-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminosalicylic acid + sulphasalazine in acute myeloid leukemia (AML), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Dose limiting toxicity (DLT) during Phase I dose escalation, Maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-513084-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513084-38-00.